Cytogenetic evaluation in myelodysplastic syndrome

Creative Commons License

Leblebici C. B.

European Society of Human Genetics, Vienna, Austria, 11 - 14 June 2022, pp.546

  • Publication Type: Conference Paper / Summary Text
  • City: Vienna
  • Country: Austria
  • Page Numbers: pp.546
  • Ankara University Affiliated: Yes

Abstract

Myelodysplastic syndrome (MDS) is a hematological malignancy that is characterized by prolonged cytopenia in the bone marrow (BM) and has a risk of conversion to acute myeloid leukemia. Morphological changes in the bone marrow are often required for diagnosis, this also needs to be correlated with other laboratory tests such as cytogenetic analysis. Cytogenetic risk grouping according to IPSS-R (Revised International Prognostic Scoring System) is important in patient followup. In this study, conventional cytogenetic(CC) and fluorescent in situ hybridization(FISH) results of MDS are presented.